ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...
Supernus Pharmaceuticals has experienced revenue growth every year since its IPO in 2021, reaching $667m in 2022. The company has expanded its product portfolio through acquisitions, including the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results